UNCY 0.44 Unicycive Therapeutics, Inc.
| Range: | 0.202-1.818 | Vol Avg: | 2358946 | Last Div: | 0 | Changes: | -0.03 |
| Beta: | 2.35 | Cap: | 0.04B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Jul 12 2021 | Empoloyees: | 14 | ||
| CUSIP: | 90466Y103 | CIK: | 0001766140 | ISIN: | US90466Y1038 | Country: | US |
| CEO: | Dr. Shalabh K. Gupta M.D., MPA | Website: | https://www.unicycive.com | ||||
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow